Rate of discontinuation and reasons for discontinuation of intravesical onabotulinum toxin A treatment in patients with symptomatic Overactive Bladder (OAB)

Bibliographic Details
Main Authors:	G. Scrimgeour, K. Aleksejeva, R. Axell, H. Yasmin, M. Nadeem, M.H. Pakzad, R. Hamid, J.L. Ockrim, T.J. Greenwell
Format:	Article
Language:	English
Published:	Elsevier 2020-07-01
Series:	European Urology Open Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168320331244

Internet